These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 10804088)

  • 1. The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma.
    Arastéh K; Hannah A
    Oncologist; 2000; 5 Suppl 1():28-31. PubMed ID: 10804088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.
    Vajkoczy P; Thurnher A; Hirth KP; Schilling L; Schmiedek P; Ullrich A; Menger MD
    Oncologist; 2000; 5 Suppl 1():16-9. PubMed ID: 10804086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications.
    Ellis LM; Takahashi Y; Liu W; Shaheen RM
    Oncologist; 2000; 5 Suppl 1():11-5. PubMed ID: 10804085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGF receptor signaling in tumor angiogenesis.
    McMahon G
    Oncologist; 2000; 5 Suppl 1():3-10. PubMed ID: 10804084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy.
    Harris AL
    Oncologist; 2000; 5 Suppl 1():32-6. PubMed ID: 10804089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation.
    Verheul HM; Hoekman K; Jorna AS; Smit EF; Pinedo HM
    Oncologist; 2000; 5 Suppl 1():45-50. PubMed ID: 10804091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kaposi's sarcoma cells of different etiologic origins respond to HIV-Tat through the Flk-1/KDR (VEGFR-2): relevance in AIDS-KS pathology.
    Morini M; Benelli R; Giunciuglio D; Carlone S; Arena G; Noonan DM; Albini A
    Biochem Biophys Res Commun; 2000 Jun; 273(1):267-71. PubMed ID: 10873597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma.
    Cornali E; Zietz C; Benelli R; Weninger W; Masiello L; Breier G; Tschachler E; Albini A; Stürzl M
    Am J Pathol; 1996 Dec; 149(6):1851-69. PubMed ID: 8952523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VEGF in brain tumors.
    Machein MR; Plate KH
    J Neurooncol; 2000; 50(1-2):109-20. PubMed ID: 11245271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-Src mediates mitogenic signals and associates with cytoskeletal proteins upon vascular endothelial growth factor stimulation in Kaposi's sarcoma cells.
    Munshi N; Groopman JE; Gill PS; Ganju RK
    J Immunol; 2000 Feb; 164(3):1169-74. PubMed ID: 10640727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
    Haspel HC; Scicli GM; McMahon G; Scicli AG
    Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma.
    Brown LF; Tognazzi K; Dvorak HF; Harrist TJ
    Am J Pathol; 1996 Apr; 148(4):1065-74. PubMed ID: 8644848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development.
    Samaniego F; Markham PD; Gendelman R; Watanabe Y; Kao V; Kowalski K; Sonnabend JA; Pintus A; Gallo RC; Ensoli B
    Am J Pathol; 1998 Jun; 152(6):1433-43. PubMed ID: 9626048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma.
    Tulpule A; Scadden DT; Espina BM; Cabriales S; Howard W; Shea K; Gill PS
    J Clin Oncol; 2000 Feb; 18(4):716-23. PubMed ID: 10673512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma.
    Masood R; Cai J; Zheng T; Smith DL; Naidu Y; Gill PS
    Proc Natl Acad Sci U S A; 1997 Feb; 94(3):979-84. PubMed ID: 9023368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.
    Fong TA; Shawver LK; Sun L; Tang C; App H; Powell TJ; Kim YH; Schreck R; Wang X; Risau W; Ullrich A; Hirth KP; McMahon G
    Cancer Res; 1999 Jan; 59(1):99-106. PubMed ID: 9892193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
    Ning S; Laird D; Cherrington JM; Knox SJ
    Radiat Res; 2002 Jan; 157(1):45-51. PubMed ID: 11754641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis inhibition in solid tumors.
    Rosen LS
    Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor is a potent angiogenic factor in AIDS-associated Kaposi's sarcoma-derived spindle cells.
    Nakamura S; Murakami-Mori K; Rao N; Weich HA; Rajeev B
    J Immunol; 1997 May; 158(10):4992-5001. PubMed ID: 9144519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.